Effects of Bathsalts Pt.2
Effects of Bathsalts Pt.2 – Bath Salt Addiction Addiction treatment centers across the nation are starting to see patients turning up with familiar addictive behaviors related to a new legal drug on the market that is being sold as bath salts. The bath salts are sold by names like Charge, White Knight and Sky Vanilla and all have labels stating they are not intended for human consumption. But it appears they are actually produced for exactly that, human consumption, with the “bath salts” description clearly being a sham and a clever, but insidious way to get around substance abuse laws. The problem is that the laws do not cover many of the new substances showing up in mini-marts and gas stations around the country. Last year, many states scrambled to address a lack of laws on synthetic marijuana that people were smoking to get high. Lawmakers in several states moved quickly to ban the fake pot and now there are even more new variations of harder drugs showing up. The bath salts are sold in packets about the size of a tea bag, which is clearly not enough “salt” for a real “bath” but evidently contains plenty of the potent, but unrestricted drug mephedrone, which is a stimulant and produces a high similar to cocaine or methamphetamine. Because the packets come with the disclaimer, “not for human consumption” they are not subject to regulation even though they can contain a potpourri of dangerous chemicals. Mephedrone is a derivative substance similar to amphetamines and the side effects are about …
Seattle Genetics' ASH 2012 Presentations Highlight ADCETRIS® and …
Filed under: drug treatment news 2012
ADCETRIS received accelerated approval from the U.S. Food and Drug Administration (FDA) for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two …
Read more on DailyFinance
PropThink: Titan Files NDA on Probuphine; Partner Waits
Filed under: drug treatment news 2012
By Jason Napodano, CFA. Monday morning, Titan Pharmaceuticals (OTC:TTNP) announced it had filed a New Drug Application (NDA) to the U.S. FDA on Probuphine for the maintenance treatment of opioid dependence in adults patients (Press Release). … In …
Read more on Reuters